(Q48391405)

11 February 2018

title

Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients. (English)

1 reference

11 February 2018

0 references

0 references

1 reference

6

Shiwei Duan

1 reference

11 February 2018

author name string

Qinghe Xing

1

1 reference

11 February 2018

Rui Gao

2

1 reference

11 February 2018

Huafang Li

3

1 reference

11 February 2018

Guoyin Feng

4

1 reference

11 February 2018

Mingqing Xu

5

1 reference

11 February 2018

Junwei Meng

7

1 reference

11 February 2018

Aiping Zhang

8

1 reference

11 February 2018

Shengying Qin

9

1 reference

11 February 2018

Lin He

10

1 reference

11 February 2018

publication date

1 October 2006

1 reference

11 February 2018

published in

Pharmacogenomics

1 reference

11 February 2018

volume

7

1 reference

11 February 2018

issue

7

1 reference

11 February 2018

page(s)

987-993

1 reference

11 February 2018

The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors

cites work

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.987

abcb1ab P-glycoprotein is involved in the uptake of citalopram and trimipramine into the brain of mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.987

Olanzapine penetration into brain is greater in transgenic Abcb1a P-glycoprotein-deficient mice than FVB1 (wild-type) animals

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.987

Population pharmacokinetic analysis of drug-drug interactions among risperidone, bupropion, and sertraline in CF1 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.987

Association between multidrug resistance 1 (MDR1) gene polymorphisms and therapeutic response to bromperidol in schizophrenic patients: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.987

Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.987

Risperidone versus haloperidol in psychotic patients with disturbing neuroleptic-induced extrapyramidal symptoms: a double-blind, multi-center trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.987

A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.987

Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.987

In vitro P-glycoprotein affinity for atypical and conventional antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.987

P-glycoprotein interaction with risperidone and 9-OH-risperidone studied in vitro, in knock-out mice and in drug-drug interaction experiments

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.987

The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.987

Localization of multidrug resistance-associated DNA sequences to human chromosome 7.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.987

ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.987

Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.987

Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.987

A new structural model for P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.987

Identification of functionally variant MDR1 alleles among European Americans and African Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.987

Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.987

Inhibition of genes expression of SARS coronavirus by synthetic small interfering RNAs.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.987

The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.987

Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.987

Digoxin pharmacokinetics and MDR1 genetic polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.987

21 January 2018

Identifiers

DOI

10.2217/14622416.7.7.987

1 reference

11 February 2018

PubMed ID

17054409

1 reference

11 February 2018